India will need to front load its investments substantially to almost double the number of people on ARV treatment in less than five years, Minister for Health and Family Welfare, J P Nadda said at UNGA.
United Nations: With over 80 per cent of the affordable and quality anti-retroviral drugs used globally to treat AIDS supplied by Indian pharmaceutical industry, India has sought flexibilities in IPR under a global trade agreement to back its endeavour of ending the deadly disease by 2030.
“We are well aware of the role that generic pharmaceutical manufacturers from India have played in initiating anti-retroviral (ARV) treatment for over 17 million people by providing affordable and high quality ARV drugs. We will continue to provide this support to the global community in ending AIDS by 2030,” Minister for Health and Family Welfare J P Nadda said at a panel discussion on the sidelines of the high-level General Assembly meeting on HIV/AIDS.
He said India reminds the global community that, to continue the important role its generic pharmaceutical industry plays in the treatment of HIV/AIDS, flexibilities related to the World Trade Organisation Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) need to continue.
Please click here to read more.